Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated for symptomatic treatment of focal spasticity of:
- Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older
- Upper limbs in paediatric cerebral palsy patients, two years of age or older.
Please click here to see the full therapeutic indications.
![](https://wave-eu-west-1.s3.eu-west-1.amazonaws.com/websites/ipsenhub_co_uk/wp-content/uploads/2024/03/Dysport-Paediatric-image-2048x1366-1.jpeg)
CLIMB Online
Paediatric Spasticity
![](https://wave-eu-west-1.s3.eu-west-1.amazonaws.com/websites/ipsenhub_co_uk/wp-content/uploads/2024/08/DYS-UK-008779-thumbnail.png)
Dysport® Dosing Map for Paediatric Spasticity
A downloadable reference guide to the dosing of Dysport® for the treatment of paediatric spasticity.
DYS-UK-008779
![](https://wave-eu-west-1.s3.eu-west-1.amazonaws.com/websites/ipsenhub_co_uk/wp-content/uploads/2024/08/DYS-UK-008484-thumbnail.png)
Goal Setting for Children with Spasticity
30 minutes
An overview of goal setting for children with spasticity including the Canadian Occupation Performance Measure (COPM) and Goal Attainment Scaling (GAS).
DYS-UK-008484
![](https://wave-eu-west-1.s3.eu-west-1.amazonaws.com/websites/ipsenhub_co_uk/wp-content/uploads/2024/08/DYS-UK-008492-thumbnail.png)
Dysport® Clinical Trial Data – eLearning Module
45 minutes
An overview of the phase 3 clinical studies of Dysport® in children with upper and lower limb spasticity
DYS-UK-008492
![](https://wave-eu-west-1.s3.eu-west-1.amazonaws.com/websites/ipsenhub_co_uk/wp-content/uploads/2024/03/wave-1-2048x358-1.png)